TB-500 + BPC-157 Combo

Two famous repair-model compounds in one box, on the strength of a theory.

TB-500 + BPC-157 Combo is a research-use preparation supplying two synthetic peptides together: BPC-157, a 15-residue peptide sequence (GEPPPGKPADDAGLV, approximately 1419.5 Da) derived from a protein in human gastric juice, and TB-500, the acetylated 7-residue thymosin beta-4 fragment Ac-LKKTETQ (approximately 889.0 Da). In the only published controlled comparison, an Achilles tendon transection model in 32 rats, combined administration conferred no additional benefit relative to either agent administered alone.

Some product pages exist because of science. This one exists because of ordering habits.

These two compounds are the most-paired items in the entire research-peptide world. The forums decided they belong together years ago, the way peanut butter and jam ended up in the same aisle.

The theory behind the pairing's genuinely tidy. BPC-157's studied for blood supply reaching damaged tissue, TB-500 for cells migrating toward it. Supply and movement. Two halves of one repair story.

Tidy theories are where this shelf gets into trouble, so the research section below does something you won't see on most combo pages.

It quotes the one controlled experiment that actually checked.

Movement plus supply. The theory is tidy. Tidy is not tested.

The individual mechanisms live on their own pages, and in one sentence each: BPC-157 is studied for angiogenesis, the building of supply roads, and TB-500 for actin dynamics, the machinery of cell movement.

Biology isn't modular the way the theory needs it to be. Two pathways that look complementary on a whiteboard can turn out redundant, or interfering, or irrelevant to each other once they're in actual tissue. Peanut butter and jam only works because somebody tried it.

Which is why the only thing that settles a combination question is a combination experiment.

Here's the honest part. One exists.

And its result is the reason this page reads the way it does.

One controlled study looked at the combination. Read what it found.

One controlled animal study has directly tested this combination against its parts. Verbatim from it: "Combined BPC-157 and TB-500 did not confer additional benefits compared to either alone."

One rodent study isn't a final answer, and it's worth saying the components were given at particular amounts in one particular model. Limits noted. We'd say the same about a study that went our way.

But the current score is this: theory says two is better, and the one experiment that checked says it wasn't.

We sell the combo because researchers order it together. What we won't do is tell you the pairing has evidence behind it when the one direct test points the other way.

Order it for the convenience. Don't order it for the study, because the study said no.

What is actually in the vial. Two synthetic peptides supplied together. BPC-157 at fifteen residues and 1419.5 daltons, TB-500 at seven residues and 889.0 daltons. Neither one is thymosin beta-4 itself, and neither occurs as a free peptide in nature.

A blend makes the analytics harder. Purity methods get validated one analyte at a time. A vial holding two peptides needs a method that resolves both parent peaks plus the degradants of each, so a single combined percentage would not be analytically meaningful even in principle.

Status, said once. Research use only, not for human or veterinary use. WADA lists BPC-157 by name under S0 for 2026, and covers thymosin beta-4 and its derivatives including TB-500 under S2.3. Health Canada named both compounds in its April 2026 advisory on peptides bought online and states that peptides are generally regulated as prescription drugs in Canada. Both sit in the FDA table of bulk drug substances nominated then withdrawn, so neither is on the 503A bulks list.